The rearrangement of anaplastic lymphoma kinase (ALK) plays an important role in promoting the occurrence and development of lung cancer [56], thus it becomes an important clinical targeted treatment of ALK-positive NSCLC [57]. This evidence concerns the gene ALK and non-small cell lung carcinoma.